āĻšā§āĻŽALNOV âĸ EPA
add
Novacyt SA
ā§Ļ.ā§Šā§¯âŦ
ā§Ģ āĻŽāĻžāϰā§āĻ, ā§Ŧ:ā§Šā§Ļ:ā§Ļā§Ļ AM GMT +ā§§ · EUR · EPA · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Ļ.ā§Ēā§ĻâŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Ļ.ā§Šā§ŽâŦ - ā§Ļ.ā§Ēā§ĻâŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§Ļ.ā§Šā§ŽâŦ - ā§Ļ.ā§ā§ĒâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
⧍.ā§Žā§ŠÂ āĻā§ EUR
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
ā§§ā§Ŧ.⧝ā§Ē āĻšāĻž
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
EPA
āĻŦāĻžāĻāĻžāϰ āϏāĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
| (GBP) | āĻā§āύ ⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§Ēā§Ž.⧝ā§Ŧ āϞāĻž | -ā§§.ā§Žā§Ļ% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§Ŧā§Ē.ā§Šā§¨Â āϞāĻž | -ā§Ŧā§Š.ā§¨ā§Ž% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§Šā§§.ā§ā§§Â āϞāĻž | ā§Ŧā§Ē.ā§§ā§% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | -ā§Ŧā§Ē.ā§ā§Ŧ | ā§Ŧā§Š.ā§Ģā§§% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | â | â |
EBITDA | -⧍⧧.ā§Ŧā§Ŧ āϞāĻž | ā§Šā§¯.ā§Žā§Ē% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | ā§Š.ā§Žā§Ļ% | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (GBP) | āĻā§āύ ⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ⧍.ā§Šā§Â āĻā§ | -ā§¨ā§Ž.ā§Ļā§§% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Ŧ.ā§¨ā§¯Â āĻā§ | -ā§Šā§Ŧ.ā§ā§Ļ% |
āĻŽā§āĻ āĻĻāĻžā§ | ⧍.ā§¨ā§§Â āĻā§ | -ā§¨ā§Š.ā§Žā§¨% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Ē.ā§Ļā§ŽÂ āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§.ā§Ļā§Ŧ āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§Ļ.ā§Ŧā§Ž | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -⧧⧍.ā§Ŧā§Š% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | -ā§§ā§Ģ.ā§Šā§Ē% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
| (GBP) | āĻā§āύ ⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§Šā§§.ā§ā§§Â āϞāĻž | ā§Ŧā§Ē.ā§§ā§% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | -⧍ā§.ā§Šā§Â āϞāĻž | ā§Šā§¯.ā§ā§Ŧ% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§Žā§Ģ.ā§Ģā§Ļ āĻšāĻž | ā§Žā§Ē.⧝⧧% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§Ģ.ā§Ģā§Ģ āϞāĻž | -ā§¨ā§Ž.⧝⧍% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | -ā§Šā§Š.ā§ā§ŠÂ āϞāĻž | ā§Šā§¯.ā§Šā§§% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -⧧⧍.ā§Ģā§¯Â āϞāĻž | ā§Žā§Ž.⧝ā§Ģ% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and VÊlizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
āϏāĻŋāĻāĻ
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
ā§Š āĻā§āϞ, ⧍ā§Ļā§Ļā§Ŧ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§¨ā§Šā§Ē